Elnura Y. Izteleuova

Mrs. Elnura Y. Izteleuova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2025 in Plants
Verified
Journal Article
Open access
PDF file
EIElnura Y. Izteleuova
Elnura Y. Izteleuova
GZGulsim Zhumashova
Gulsim Zhumashova
TBTolkyn Bekezhanova
Tolkyn Bekezhanova
ZAZOYA ALLLAMBERGENOVA
ZOYA ALLLAMBERGENOVA
KZKarlygash Zhaparkulova
Karlygash Zhaparkulova
Izabela Korona-GłowniakIzabela Korona-Głowniak
Izabela Korona-Głowniak
This review systematically compiles and evaluates current research on the ethnopharmacology, phytochemistry, pharmacological effects, and the clinical potential of plants of the genus Ribes L. Ribes species have long been used in traditional medicine for cardiovascular diseases, hepatitis, gastrointestinal ailments, hyperlipidemia, and detoxification, owing to their rich content of phenolic glycosides, flavonoids, proanthocyanidins, and polysaccharides. We analyze data from in vitro, in vivo, and clinical studies, focusing on antioxidant, anti-inflammatory, antibacterial, antiviral, antitumor, and vision-protective properties of extracts and isolated compounds. Particular attention is given to R. nigrum, a species recognized in French and British pharmacopeias for its antioxidant, anti-inflammatory, antimicrobial, and immunomodulatory properties. Our synthesis reveals significant gaps: many Ribes spp. remain poorly characterized chemically; toxicology and pharmacokinetics are seldom studied; clinical trials are limited in number and rigor. We propose that future research should prioritize the comprehensive metabolomic and chemoprofiling of understudied Ribes species; standardized safety and dosage studies; the elucidation of absorption, distribution, metabolism, and excretion (ADME) of key bioactives; and well-designed randomized clinical trials to validate traditional uses and establish therapeutic efficacy. Our review demonstrates that Ribes spp. are promising sources for novel phytopharmaceutical agents and functional foods, but that translational and regulatory research is essential to move from traditional claims toward evidence-based medical applications.

20 March 2026 in West Kazakhstan Medical Journal
Verified
Journal Article
Open access
EIElnura Y. Izteleuova
Elnura Y. Izteleuova
IKIzabela Korona-Glowniak
Izabela Korona-Glowniak
GZGulsim T. Zhumashova
Gulsim T. Zhumashova
TBTolkyn S. Bekezhanova
Tolkyn S. Bekezhanova
ASAsanali E. Sakipov
Asanali E. Sakipov
MTMeruyert I. Tleubayeva
Meruyert I. Tleubayeva
This article presents a detailed analysis of the herbal medicinal product market in the Republic of Kazakhstan from 2020 to 2024. The study examines key factors influencing market development, including assortment composition, the competitive landscape, retail sales dynamics, and the balance between imported and domestically produced herbal medicines. The findings show that only 54 herbal medicinal products with ATC codes are registered, representing 0.77% of all medicines, with domestic production remaining limited at around 15% of the market. The assortment is dominated by R05 cough and cold preparations, followed by sedatives, general tonics, and digestive system agents. Retail data indicate stable demand, with notable growth in solid dosage forms and a recent decline in liquid forms. The analysis highlights Kazakhstan’s continued dependence on foreign manufacturers and underscores the need to strengthen domestic phytopharmaceutical production to leverage the country’s significant botanical potential.